Identification of CD160-TM as a tumor target on triple negative breast cancers: possible therapeutic applications.
Antibody-based therapy
CD160-TM
TNBC
Tumor antigen
Journal
Breast cancer research : BCR
ISSN: 1465-542X
Titre abrégé: Breast Cancer Res
Pays: England
ID NLM: 100927353
Informations de publication
Date de publication:
15 Feb 2024
15 Feb 2024
Historique:
received:
13
11
2023
accepted:
12
02
2024
medline:
16
2
2024
pubmed:
16
2
2024
entrez:
15
2
2024
Statut:
epublish
Résumé
Despite major therapeutic advances, triple-negative breast cancer (TNBC) still presents a worth prognosis than hormone receptors-positive breast cancers. One major issue relies in the molecular and mutational heterogeneity of TNBC subtypes that is reinforced by the absence of reliable tumor-antigen that could serve as a specific target to further promote efficient tumor cell recognition and depletion. CD160 is a receptor mainly expressed by NK lymphocytes and presenting two isoforms, namely the GPI-anchored form (CD160-GPI) and the transmembrane isoform (CD160-TM). While CD160-GPI is constitutively expressed on resting cells and involved in the generation of NK cells' cytotoxic activity, CD160-TM is neo-synthesized upon activation and promotes the amplification of NK cells' killing ability. CD160 expression was assessed by immunohistochemistry (IHC) and flow cytometry on TNBC patient biopsies or cell lines, respectively. Antibody (Ab)-mediated tumor depletion was tested in vitro by performing antibody-dependent cell cytotoxicity (ADCC) and phagocytosis (ADCP) assays, and in vivo on a TNBC mouse model. Preliminary data obtained by IHC on TNBC patients' tumor biopsies revealed an unconventional expression of CD160 by TNBC tumor cells. By using a specific but conformation-dependent anti-CD160-TM Ab, we established that CD160-TM, but not CD160-GPI, was expressed by TNBC tumor cells. A conformation-independent anti-CD160-TM mAb (22B12; muIgG2a isotype) was generated and selected according to pre-defined specificity and functional criterions. In vitro functional assays demonstrated that ADCC and ADCP could be induced in the presence of 22B12, resulting in TNBC cell line apoptosis. The ability of 22B12 to exert an in vivo anti-tumor activity was also demonstrated on a TNBC murine model. Our data identify CD160-TM as a tumor marker for TNBC and provide a rational for the use of anti-CD160-TM antibodies as therapeutic tools in this tumor context.
Sections du résumé
BACKGROUND
BACKGROUND
Despite major therapeutic advances, triple-negative breast cancer (TNBC) still presents a worth prognosis than hormone receptors-positive breast cancers. One major issue relies in the molecular and mutational heterogeneity of TNBC subtypes that is reinforced by the absence of reliable tumor-antigen that could serve as a specific target to further promote efficient tumor cell recognition and depletion. CD160 is a receptor mainly expressed by NK lymphocytes and presenting two isoforms, namely the GPI-anchored form (CD160-GPI) and the transmembrane isoform (CD160-TM). While CD160-GPI is constitutively expressed on resting cells and involved in the generation of NK cells' cytotoxic activity, CD160-TM is neo-synthesized upon activation and promotes the amplification of NK cells' killing ability.
METHODS
METHODS
CD160 expression was assessed by immunohistochemistry (IHC) and flow cytometry on TNBC patient biopsies or cell lines, respectively. Antibody (Ab)-mediated tumor depletion was tested in vitro by performing antibody-dependent cell cytotoxicity (ADCC) and phagocytosis (ADCP) assays, and in vivo on a TNBC mouse model.
RESULTS
RESULTS
Preliminary data obtained by IHC on TNBC patients' tumor biopsies revealed an unconventional expression of CD160 by TNBC tumor cells. By using a specific but conformation-dependent anti-CD160-TM Ab, we established that CD160-TM, but not CD160-GPI, was expressed by TNBC tumor cells. A conformation-independent anti-CD160-TM mAb (22B12; muIgG2a isotype) was generated and selected according to pre-defined specificity and functional criterions. In vitro functional assays demonstrated that ADCC and ADCP could be induced in the presence of 22B12, resulting in TNBC cell line apoptosis. The ability of 22B12 to exert an in vivo anti-tumor activity was also demonstrated on a TNBC murine model.
CONCLUSIONS
CONCLUSIONS
Our data identify CD160-TM as a tumor marker for TNBC and provide a rational for the use of anti-CD160-TM antibodies as therapeutic tools in this tumor context.
Identifiants
pubmed: 38360636
doi: 10.1186/s13058-024-01785-x
pii: 10.1186/s13058-024-01785-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
28Informations de copyright
© 2024. The Author(s).
Références
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.
pubmed: 33538338
doi: 10.3322/caac.21660
Eliyatkin N, Yalcin E, Zengel B, Aktas S, Vardar E. Molecular classification of breast carcinoma: from traditional, old-fashioned way to a new age, and a new way. J Breast Health. 2015;11:59–66.
pubmed: 28331693
pmcid: 5351488
doi: 10.5152/tjbh.2015.1669
Lukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanislawek A. Breast Cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review. Cancers (Basel). 2021;13.
Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger. Ann Oncol. 2019;30:1194–220.
pubmed: 31161190
doi: 10.1093/annonc/mdz173
Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007;109:1721–8.
pubmed: 17387718
doi: 10.1002/cncr.22618
Boyle P. Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol. 2012;23 Suppl 6:vi7–12.
Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429–34.
pubmed: 17671126
doi: 10.1158/1078-0432.CCR-06-3045
Urru SAM, Gallus S, Bosetti C, Moi T, Medda R, Sollai E, et al. Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients. BMC Cancer. 2018;18:56.
pubmed: 29310602
pmcid: 5759886
doi: 10.1186/s12885-017-3969-y
Lee J. Current treatment landscape for early triple-negative breast cancer (TNBC). J Clin Med. 2023;12.
Zhang M, Song J, Yang H, Jin F, Zheng A. Efficacy and safety of PD-1/PD-L1 inhibitors in triple-negative breast cancer: a systematic review and meta-analysis. Acta Oncol. 2022;61:1105–15.
pubmed: 35939538
doi: 10.1080/0284186X.2022.2106795
Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol. 2019;30:397–404.
pubmed: 30475950
doi: 10.1093/annonc/mdy517
Emens LA, Cruz C, Eder JP, Braiteh F, Chung C, Tolaney SM, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol. 2019;5:74–82.
pubmed: 30242306
doi: 10.1001/jamaoncol.2018.4224
He R, Yuan X, Chen Z, Zheng Y. Combined immunotherapy for metastatic triple-negative breast cancer based on PD-1/PD-L1 immune checkpoint blocking. Int Immunopharmacol. 2022;113:109444.
pubmed: 36402069
doi: 10.1016/j.intimp.2022.109444
Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108–21.
pubmed: 30345906
doi: 10.1056/NEJMoa1809615
Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kummel S, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386:556–67.
pubmed: 35139274
doi: 10.1056/NEJMoa2112651
Schmid P, Cortes J, Pusztai L, McArthur H, Kummel S, Bergh J, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382:810–21.
pubmed: 32101663
doi: 10.1056/NEJMoa1910549
Yang T, Li W, Huang T, Zhou J. Immunotherapy targeting PD-1/PD-L1 in early-stage triple-negative breast cancer. J Pers Med. 2023;13.
Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S, et al. Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol. 2022;15:121.
pubmed: 36038913
pmcid: 9422136
doi: 10.1186/s13045-022-01341-0
Anumanthan A, Bensussan A, Boumsell L, Christ AD, Blumberg RS, Voss SD, et al. Cloning of BY55, a novel Ig superfamily member expressed on NK cells, CTL, and intestinal intraepithelial lymphocytes. J Immunol. 1998;161:2780–90.
pubmed: 9743336
doi: 10.4049/jimmunol.161.6.2780
Bensussan A, Gluckman E, el Marsafy S, Schiavon V, Mansur IG, Dausset J, et al. BY55 monoclonal antibody delineates within human cord blood and bone marrow lymphocytes distinct cell subsets mediating cytotoxic activity. Proc Natl Acad Sci USA. 1994;91:9136–40.
pubmed: 8090781
pmcid: 44762
doi: 10.1073/pnas.91.19.9136
Fons P, Chabot S, Cartwright JE, Lenfant F, L’Faqihi F, Giustiniani J, et al. Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells. Blood. 2006;108:2608–15.
pubmed: 16809620
doi: 10.1182/blood-2005-12-019919
Ortonne N, Ram-Wolff C, Giustiniani J, Marie-Cardine A, Bagot M, Mecheri S, et al. Human and mouse mast cells express and secrete the GPI-anchored isoform of CD160. J Invest Dermatol. 2011;131:916–24.
pubmed: 21191401
doi: 10.1038/jid.2010.412
Sako N, Schiavon V, Bounfour T, Dessirier V, Ortonne N, Olive D, et al. Membrane expression of NK receptors CD160 and CD158k contributes to delineate a unique CD4+ T-lymphocyte subset in normal and mycosis fungoides skin. Cytometry A. 2014;85:869–82.
pubmed: 25044837
doi: 10.1002/cyto.a.22512
Agrawal S, Marquet J, Freeman GJ, Tawab A, Bouteiller PL, Roth P, et al. Cutting edge: MHC class I triggering by a novel cell surface ligand costimulates proliferation of activated human T cells. J Immunol. 1999;162:1223–6.
pubmed: 9973372
doi: 10.4049/jimmunol.162.3.1223
Cai G, Anumanthan A, Brown JA, Greenfield EA, Zhu B, Freeman GJ. CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator. Nat Immunol. 2008;9:176–85.
pubmed: 18193050
doi: 10.1038/ni1554
Le Bouteiller P, Barakonyi A, Giustiniani J, Lenfant F, Marie-Cardine A, Aguerre-Girr M, et al. Engagement of CD160 receptor by HLA-C is a triggering mechanism used by circulating natural killer (NK) cells to mediate cytotoxicity. Proc Natl Acad Sci U S A. 2002;99:16963–8.
pubmed: 12486241
pmcid: 139252
doi: 10.1073/pnas.012681099
Barakonyi A, Rabot M, Marie-Cardine A, Aguerre-Girr M, Polgar B, Schiavon V, et al. Cutting edge: engagement of CD160 by its HLA-C physiological ligand triggers a unique cytokine profile secretion in the cytotoxic peripheral blood NK cell subset. J Immunol. 2004;173:5349–54.
pubmed: 15494480
doi: 10.4049/jimmunol.173.9.5349
Rabot M, El Costa H, Polgar B, Marie-Cardine A, Aguerre-Girr M, Barakonyi A, et al. CD160-activating NK cell effector functions depend on the phosphatidylinositol 3-kinase recruitment. Int Immunol. 2007;19:401–9.
pubmed: 17307798
doi: 10.1093/intimm/dxm005
Sun Z, Li Y, Zhang Z, Fu Y, Han X, Hu Q, et al. CD160 promotes NK cell functions by upregulating glucose metabolism and negatively correlates with HIV disease progression. Front Immunol. 2022;13:854432.
pubmed: 36110864
pmcid: 9469471
doi: 10.3389/fimmu.2022.854432
Tu TC, Brown NK, Kim TJ, Wroblewska J, Yang X, Guo X, et al. CD160 is essential for NK-mediated IFN-gamma production. J Exp Med. 2015;212:415–29.
pubmed: 25711213
pmcid: 4354368
doi: 10.1084/jem.20131601
D’Addio F, Ueno T, Clarkson M, Zhu B, Vergani A, Freeman GJ, et al. CD160Ig fusion protein targets a novel costimulatory pathway and prolongs allograft survival. PLoS ONE. 2013;8:e60391.
pubmed: 23593209
pmcid: 3617215
doi: 10.1371/journal.pone.0060391
El-Far M, Pellerin C, Pilote L, Fortin JF, Lessard IA, Peretz Y, et al. CD160 isoforms and regulation of CD4 and CD8 T-cell responses. J Transl Med. 2014;12:217.
pubmed: 25179432
pmcid: 4163173
doi: 10.1186/s12967-014-0217-y
Tan CL, Peluso MJ, Drijvers JM, Mera CM, Grande SM, Brown KE, et al. CD160 stimulates CD8(+) T Cell responses and is required for optimal protective immunity to listeria monocytogenes. Immunohorizons. 2018;2:238–50.
pubmed: 31022694
doi: 10.4049/immunohorizons.1800039
Feng DC, Zhu WZ, Shi X, Xiong Q, You J, Wei Q, et al. Identification of senescence-related molecular subtypes and key genes for prostate cancer. Asian J Androl. 2023;25:223–9.
pubmed: 36124532
doi: 10.4103/aja202258
Liao J, Lai H, Liu C, Zhang X, Ou Q, Li Q, et al. Plasma extracellular vesicle transcriptomics identifies CD160 for predicting immunochemotherapy efficacy in lung cancer. Cancer Sci. 2023;114:2774–86.
pubmed: 37014183
pmcid: 10323081
doi: 10.1111/cas.15804
Oumeslakht L, Aziz AI, Bensussan A, Ben MS. CD160 receptor in CLL: current state and future avenues. Front Immunol. 2022;13:1028013.
pubmed: 36420268
pmcid: 9676924
doi: 10.3389/fimmu.2022.1028013
Sun H, Xu J, Huang Q, Huang M, Li K, Qu K, et al. Reduced CD160 expression contributes to impaired NK-cell function and poor clinical outcomes in patients with HCC. Cancer Res. 2018;78:6581–93.
pubmed: 30232222
doi: 10.1158/0008-5472.CAN-18-1049
Sun N, Luo Y, Zheng B, Zhang Z, Zhang C, Zhang Z, et al. A novel immune checkpoints-based signature to predict prognosis and response to immunotherapy in lung adenocarcinoma. J Transl Med. 2022;20:332.
pubmed: 35879761
pmcid: 9310422
doi: 10.1186/s12967-022-03520-6
Tang L, Zhang Z, Fan J, Xu J, Xiong J, Tang L, et al. Comprehensively analysis of immunophenotyping signature in triple-negative breast cancer patients based on machine learning. Front Pharmacol. 2023;14:1195864.
pubmed: 37426809
pmcid: 10328722
doi: 10.3389/fphar.2023.1195864
Giustiniani J, Bensussan A, Marie-Cardine A. Identification and characterization of a transmembrane isoform of CD160 (CD160-TM), a unique activating receptor selectively expressed upon human NK cell activation. J Immunol. 2009;182:63–71.
pubmed: 19109136
doi: 10.4049/jimmunol.182.1.63
Giustiniani J, Alaoui SS, Marie-Cardine A, Bernard J, Olive D, Bos C, et al. Possible pathogenic role of the transmembrane isoform of CD160 NK lymphocyte receptor in paroxysmal nocturnal hemoglobinuria. Curr Mol Med. 2012;12:188–98.
pubmed: 22172098
doi: 10.2174/156652412798889081
Gauci ML, Giustiniani J, Lepelletier C, Garbar C, Thonnart N, Dumaz N, et al. The soluble form of CD160 acts as a tumor mediator of immune escape in melanoma. Cancer Immunol Immunother. 2022;71:2731–42.
pubmed: 35428910
pmcid: 9519731
doi: 10.1007/s00262-022-03199-0
Bosma MJ, Carroll AM. The SCID mouse mutant: definition, characterization, and potential uses. Annu Rev Immunol. 1991;9:323–50.
pubmed: 1910681
doi: 10.1146/annurev.iy.09.040191.001543
Rastetter W, Molina A, White CA. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Annu Rev Med. 2004;55:477–503.
pubmed: 14746532
doi: 10.1146/annurev.med.55.091902.104249
Janani B, Vijayakumar M, Priya K, Kim JH, Prabakaran DS, Shahid M, et al. EGFR-Based targeted therapy for colorectal cancer-promises and challenges. Vaccines (Basel). 2022;10.
London M, Gallo E. Epidermal growth factor receptor (EGFR) involvement in epithelial-derived cancers and its current antibody-based immunotherapies. Cell Biol Int. 2020;44:1267–82.
pubmed: 32162758
doi: 10.1002/cbin.11340
Bagot M, Porcu P, Marie-Cardine A, Battistella M, William BM, Vermeer M, et al. IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial. Lancet Oncol. 2019;20:1160–70.
pubmed: 31253572
doi: 10.1016/S1470-2045(19)30320-1
Duvic M, Pinter-Brown LC, Foss FM, Sokol L, Jorgensen JL, Challagundla P, et al. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood. 2015;125:1883–9.
pubmed: 25605368
pmcid: 4375715
doi: 10.1182/blood-2014-09-600924